Get startedLog in
    Picture of Caliway Biopharmaceuticals Co logo

    6919 — Caliway Biopharmaceuticals Co Cashflow Statement

    0.000.00%
    tw flag iconLast trade - 00:00
    HealthcareHighly SpeculativeLarge CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Caliway Biopharmaceuticals Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUSAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-224-286-488-589-352
    Depreciation
    Non-Cash Items77.615.36.06-8.82-237
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital12.72.7630.645.8132
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Accounts Payable
    Change in Accrued Expenses
    Change in Other Liabilities
    Net Change in Other Assets & Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-111-243-424-522-426
    Capital Expenditures-14.9-14.2-9.69-11.1-17.1
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items—-456167-2,478-5,607
    Sale of Fixed Assets
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities-14.9-471157-2,489-5,624
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities6277723,0346,491-119
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash50160.12,7673,479-6,117